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Nothing is as captivating as innovative thinking and new tools.
In this issue of the Journal of Vascular Surgery, Zhang and
colleagues from Shanghai, China provide the next ﬁrst step in
developing the story of ﬂow-diversion as a tactic to treat aortic
aneurysmal disease. This retrospective description of 34 patients
undergoing repair of a spectrum of complex aortic diseases using
multiple overlapping uncovered stents, as opposed to a singular
multilayer stent system (MLS), ﬁres a shot across the bow of aortic
intervention, indicating it is time to take a closer look at this tech-
nology and what it may have to offer us in the realm of treating
aneurysms and dissections in the thoracic and renovisceral
segment, where side-branch maintenance is paramount.
True, we now sit on the precipice of the era of widespread
commercial availability of fenestrated and branched endograft
technology. This moment has been pursued with a cavalcade of
custom-modiﬁed, chimney, snorkel, and periscope ingenuity. Yet
technical challenges, skill development, cost, and time required
for custom manufacturing remain concerns. The need and desire
for off-the-shelf complex aneurysm endografting is evident;
however, this may not be realistic in all care arenas. A more direct
and easier way to address urgent and emergent scenarios is wanted.
This report tries to convey ﬂow-diversion technology as one
possible option. Recent communication of available reports of arte-
rial, including aortic, use of MLS was encouraging.1 Shorteroperating room time, simplicity in concept, and less radiation are
possible beneﬁts. But delivery platforms are not signiﬁcantly
smaller than available endografts, and precision of deployment is
demanding.
This report must be taken with both interest and suspicion.
Only eight (23%) of 34 treated aortas were degenerative aneu-
rysms. Most were pseudoaneurysms and dissections, a hemody-
namic potpourri. Inclusion criteria described would have been
within commercially available indications for use. The average
lesion size was only 5.6 cm, and there was less than 12-month
mean follow-up. Over 30% had residual ﬂow at 6 months. Pressure
drop in the pseudoaneurysm tested was only 15 mm Hg; certainly
challenging to treatment convention and less than clinical surety.
Also, are we supposed to take it on face value that the
purported hemodynamic effects with MLS are true? The case
reports touting these beneﬁcial effects cite ﬂow dynamic data
from the corporate website where commercially available MLSs
are of aortic sizes. Early case descriptions and successes were
lauded, but newer information both in the Journal of Vascular
Surgery2 and described at the recent Veith Symposium 2012 report
rupture and complications. If this ﬂow-diversion theory is true,
why are we still challenged with endoleak after endografting?
Why did aneurysm wiring historically fail miserably? An apropos
letter to the editor of the Journal of Vascular Surgery regarding
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and molecular investigation of the MLS, thrombus, and aortic wall
interface.3 Herein, sac entrance length is deﬁned and described as
important. What will be the required aortic length of treatment?
Would it require involvement of signiﬁcant normal aorta? There
must be a plea for basic work and in-depth in vivo animal testing
to further deﬁne and describe hemodynamic effects on various
morphologies. And what about the fate of target branch vessels?
While promising patency is suggested early, what will be later
effects, and will they now be relegated to open reconstruction
when disease processes involve them? A prospective registry for
MLS use in the aorta is ongoing in France, thus more rigorous
information is hopefully forthcoming.
This novel approach is ﬁnding a voice, but remains currently
sophomoric. Reports of use continue to mount.4 Just as our profes-
sion continues to challenge and scrupulously investigate endograft
exclusionary therapy, we must demand the same of ﬂow-diversion
technologies with careful, tempered, and rational use. Zhang andcolleagues have provided another rung on the ladder. Let us see if
it climbs to anywhere.REFERENCES
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